Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 8/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | USP1 | O94782 | 5/20 | 0.44 |
| ▸ | WDR48 | Q8TAF3 | 5/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24858391 | 0.83 | NOTUM (0.54) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL21449052 | 0.82 | NOTUM (0.57) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL12411773 | 0.80 | NOTUM (0.63) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL10447781 | 0.79 | NOTUM (0.78) | NOTUMCYP19A1BRS3KEAP1 | |
| SCHEMBL29084872 | 0.79 | NOTUM (0.61) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL6877497 | 0.78 | NOTUM (0.60) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL12844428 | 0.77 | CYP19A1 (0.59) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL4921031 | 0.77 | NOTUM (0.58) | NOTUMCYP19A1BRS3KEAP1ADRB2 | |
| SCHEMBL533418 | 0.77 | NOTUM (0.58) | NOTUMCYP19A1USP1WDR48USP7 | |
| SCHEMBL28236707 | 0.77 | NOTUM (0.63) | NOTUMCYP19A1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081310-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024006544-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | SIGILON THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20220000789-A1 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | MYD88, CD4, CD74 | NOTUM 3959/4885CYP19A1 3768/4885USP1 1065/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | NOTUM 4207/4885CYP19A1 186/4885USP1 3583/4885 |
| US-20220000789-A1 | IMPLANTABLE DEVICES FOR CELL THERAPY AND RELATED METHODS | CD47, CALR, NPSR1 | NOTUM 4419/4885CYP19A1 4139/4885USP1 1407/4885 |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | TGFB2, TGFB1, COL2A1 | NOTUM 2611/4885CYP19A1 723/4885USP1 4127/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | NOTUM 4762/4885CYP19A1 2680/4885USP1 2368/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | NOTUM 4609/4885CYP19A1 1590/4885USP1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.